Boards: Atara Biotherapeutics, Crinetics Pharmaceuticals, Neumora Therapeutics, Ultragenyx Pharmaceutical.

Matthew K. Fust is a board member and advisor to life sciences companies. He serves as a director of Nasdaq-listed Atara Biotherapeutics, Crinetics Pharmaceuticals, Neumora Therapeutics, and Ultragenyx Pharmaceutical.

Matthew consults with life sciences companies on corporate finance and strategy. Previously, he served as the chief financial officer of biopharmaceutical companies Onyx Pharmaceuticals, Jazz Pharmaceuticals, and ALZA Corp., and he was a management consultant in Andersen Consulting’s health-care strategy practice.

Matthew is an advocate for corporate board diversity, with a focus on lesbian, gay, bisexual, transgender, and queer (LGBTQ) inclusion. He is senior advisor to the OutQUORUM corporate board initiative of Out Leadership and has been a board candidate mentor for the Boardroom Ready program of Women in Bio.

Matthew has a master of business administration from the Stanford University Graduate School of Business and a bachelor of science in accounting from the University of Minnesota.